葛兰素史克计划出售其在分拆出来的 Haleon 公司所持有的 4.2% 的股份。 GSK plans to sell its 4.2% stake in spun-off Haleon.

葛兰素史克计划出售其在 Haleon 持有的剩余 4.2% 全部股份，Haleon 是葛兰素史克于 2022 年 7 月分拆出来的消费者健康业务。 GSK plans to sell its entire remaining 4.2% stake in Haleon, a consumer health business it spun off in July 2022. 此前，该公司已于 5 月、10 月和 1 月出售了部分股份。 This follows previous stake sales in May, October, and January. 此次出售是通过向机构投资者配售普通股的方式进行的，这将使葛兰素史克能够专注于疫苗和传染病，并为增强其药品库存提供资金交易。 The latest sale, conducted through a placing of ordinary shares to institutional investors, will allow GSK to focus on vaccines and infectious diseases, and fund deals to enhance its drug pipeline.